Free tool
FAERS Monitor: Azulfidine
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 020465 or its brand name (Azulfidine, Sulfasalazine). Reports on generic versions are filed under their own applications.
Reports
77,206
Serious
64,651
84% of reports
Hospitalization
21,115
Death reported
7,369
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective29,465
- rheumatoid arthritis19,619
- pain16,065
- drug intolerance13,852
- arthralgia13,559
- fatigue13,435
- joint swelling12,834
- off label use11,241
- rash11,080
- abdominal discomfort10,165
- contraindicated product administered9,780
- condition aggravated9,676
- alopecia9,550
- synovitis9,345
- arthropathy9,279
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 617 |
| 2005 | 576 |
| 2006 | 640 |
| 2007 | 694 |
| 2008 | 721 |
| 2009 | 788 |
| 2010 | 865 |
| 2011 | 1,144 |
| 2012 | 1,439 |
| 2013 | 1,320 |
| 2014 | 1,450 |
| 2015 | 2,286 |
| 2016 | 3,208 |
| 2017 | 5,103 |
| 2018 | 6,182 |
| 2019 | 7,297 |
| 2020 | 11,184 |
| 2021 | 7,160 |
| 2022 | 7,093 |
| 2023 | 5,095 |
| 2024 | 5,714 |
| 2025 | 4,546 |
| 2026 | 2,083 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,976,953 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| synovitisSignal | 9,345 | 291.7 | 283.5 | 1,306,518 |
| contraindicated product administeredSignal | 9,780 | 129.4 | 126.5 | 845,388 |
| rheumatoid arthritisSignal | 19,619 | 56.7 | 55.9 | 892,822 |
| arthropathySignal | 9,279 | 54.4 | 53.2 | 406,112 |
| drug intoleranceSignal | 13,852 | 45.4 | 44.7 | 517,992 |
| joint swellingSignal | 12,834 | 32.3 | 31.7 | 349,761 |
| abdominal discomfortSignal | 10,165 | 17.5 | 17.2 | 149,814 |
| alopeciaSignal | 9,550 | 13.9 | 13.6 | 109,547 |
| arthralgiaSignal | 13,559 | 9.1 | 9.0 | 97,127 |
| condition aggravatedSignal | 9,676 | 8.9 | 8.8 | 66,856 |
| painSignal | 16,065 | 7.3 | 7.2 | 87,442 |
| rashSignal | 11,080 | 7.1 | 7.0 | 57,559 |
| drug ineffectiveSignal | 29,465 | 6.2 | 6.2 | 134,237 |
| fatigueSignal | 13,435 | 4.8 | 4.7 | 40,797 |
| off label useSignal | 11,241 | 3.5 | 3.5 | 20,990 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.